Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26263
Title: | Medical imaging and nuclear medicine: a Lancet Oncology Commission. | Austin Authors: | Hricak, Hedvig;Abdel-Wahab, May;Atun, Rifat;Lette, Miriam Mikhail;Paez, Diana;Brink, James A;Donoso-Bach, Lluís;Frija, Guy;Hierath, Monika;Holmberg, Ola;Khong, Pek-Lan;Lewis, Jason S;McGinty, Geraldine;Oyen, Wim J G;Shulman, Lawrence N;Ward, Zachary J;Scott, Andrew M | Affiliation: | Department of Radiology and Molecular Pharmacology Programme, Memorial Sloan Kettering Cancer Center, New York, NY, USA Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA International Atomic Energy Agency, Division of Human Health, Vienna, Austria Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan Departments of Radiology and Population Science, Weill Cornell Medical College, New York, NY, USA American College of Radiology, Reston, VA, USA Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA Departments of Pharmacology and Radiology, Weill Cornell Medical College, New York, NY, USA Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA Department of Radiology, Weill Cornell Medical College, New York, NY, USA Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, Netherlands Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, Netherlands Olivia Newton-John Cancer Research Institute Molecular Imaging and Therapy School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia Center for Health Decision Science, Harvard TH Chan School of Public Health, Boston, MA, USA Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA International Atomic Energy Agency, Division of Human Health, Vienna, Austria Department of Medical Imaging, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain Université de Paris, Paris, France European Society of Radiology, Vienna, Austria Radiation Protection of Patients Unit, International Atomic Energy Agency, Vienna, Austria Department of Diagnostic Radiology, University of Hong Kong, Hong Kong Special Administrative Region, China |
Issue Date: | Apr-2021 | Date: | 2021-03-04 | Publication information: | The Lancet. Oncology 2021; 22(4): e136-e172 | Abstract: | The diagnosis and treatment of patients with cancer requires access to imaging to ensure accurate management decisions and optimal outcomes. Our global assessment of imaging and nuclear medicine resources identified substantial shortages in equipment and workforce, particularly in low-income and middle-income countries (LMICs). A microsimulation model of 11 cancers showed that the scale-up of imaging would avert 3·2% (2·46 million) of all 76·0 million deaths caused by the modelled cancers worldwide between 2020 and 2030, saving 54·92 million life-years. A comprehensive scale-up of imaging, treatment, and care quality would avert 9·55 million (12·5%) of all cancer deaths caused by the modelled cancers worldwide, saving 232·30 million life-years. Scale-up of imaging would cost US$6·84 billion in 2020-30 but yield lifetime productivity gains of $1·23 trillion worldwide, a net return of $179·19 per $1 invested. Combining the scale-up of imaging, treatment, and quality of care would provide a net benefit of $2·66 trillion and a net return of $12·43 per $1 invested. With the use of a conservative approach regarding human capital, the scale-up of imaging alone would provide a net benefit of $209·46 billion and net return of $31·61 per $1 invested. With comprehensive scale-up, the worldwide net benefit using the human capital approach is $340·42 billion and the return per dollar invested is $2·46. These improved health and economic outcomes hold true across all geographical regions. We propose actions and investments that would enhance access to imaging equipment, workforce capacity, digital technology, radiopharmaceuticals, and research and training programmes in LMICs, to produce massive health and economic benefits and reduce the burden of cancer globally. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26263 | DOI: | 10.1016/S1470-2045(20)30751-8 | Journal: | The Lancet. Oncology | PubMed URL: | 33676609 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.